作者
Gavuthami Murugesan,Rachel L. Paterson,Rakesh Kulkarni,V.F. Ilkow,Richard J. Suckling,Mary M. Connolly,V. Karuppiah,Robert Pengelly,Archana Jadhav,José Donoso,Tiaan Heunis,Wilawan Bunjobpol,Gwilym Philips,Kafayat Ololade,Daniel P. Kay,Anshuk Sarkar,Claire Barber,Ritu Raj,Carole Perot,Tressan Grant,Agatha Treveil,Andrew Walker,Marcin Dembek,Dawn Gibbs‐Howe,M. Benjamin Hock,Ricardo J. Carreira,Kate E. Atkin,Lucy Dorrell,Andrew Knox,Sarah Leonard,Mariolina Salio,Luís F. Godinho
摘要
Abstract The non-polymorphic HLA-E molecule offers opportunities for new universal immunotherapeutic approaches to chronic infectious diseases. Chronic Hepatitis B virus (HBV) infection is driven in part by T cell dysfunction due to elevated levels of the HBV envelope (Env) protein hepatitis B surface antigen (HBsAg). Here we report the characterization of three genotypic variants of an HLA-E-binding HBsAg peptide, Env 371-379, identified through bioinformatic predictions and verified by biochemical and cellular assays. Using a soluble affinity-enhanced T cell receptor (TCR) (a09b08)-anti-CD3 bispecific molecule to probe HLA-E presentation of the Env 371-379 peptides, we demonstrate that only the most stable Env 371-379 variant, L6I, elicits functional responses to a09b08-anti-CD3-redirected polyclonal T cells co-cultured with targets expressing endogenous HBsAg. Furthermore, HLA-E-Env 371-379 L6I-specific CD8 + T cells are detectable in HBV-naïve donors and people with chronic HBV after in vitro priming. In conclusion, we provide evidence for HLA-E-mediated HBV Env peptide presentation, and highlight the effect of viral mutations on the stability and targetability of pHLA-E molecules.